Trevi Therapeutics Inc (NASDAQ: TRVI) on Monday, soared 1.85% from the previous trading day, before settling in for the closing price of $6.47. Within the past 52 weeks, TRVI’s price has moved between $2.30 and $7.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -12.27%. With a float of $57.14 million, this company’s outstanding shares have now reached $93.60 million.
The extent of productivity of a business whose workforce counts for 26 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Trevi Therapeutics Inc (TRVI) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Trevi Therapeutics Inc is 40.90%, while institutional ownership is 45.73%. The most recent insider transaction that took place on Mar 25 ’25, was worth 17,365. In this transaction Chief Scientific Officer of this company sold 2,631 shares at a rate of $6.60, taking the stock ownership to the 221,373 shares. Before that another transaction happened on Mar 21 ’25, when Company’s President & CEO sold 5,263 for $6.58, making the entire transaction worth $34,625. This insider now owns 213,313 shares in total.
Trevi Therapeutics Inc (TRVI) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -12.27% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -15.24% during the next five years compared to 27.09% growth over the previous five years of trading.
Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators
Trevi Therapeutics Inc (TRVI) is currently performing well based on its current performance indicators. A quick ratio of 10.41 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.47, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.61 in one year’s time.
Technical Analysis of Trevi Therapeutics Inc (TRVI)
The latest stats from [Trevi Therapeutics Inc, TRVI] show that its last 5-days average volume of 1.15 million was inferior to 1.85 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 92.34%. Additionally, its Average True Range was 0.41.
During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 84.10%, which indicates a significant decrease from 94.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.29% in the past 14 days, which was lower than the 101.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.68, while its 200-day Moving Average is $3.88. Now, the first resistance to watch is $6.73. This is followed by the second major resistance level at $6.87. The third major resistance level sits at $7.04. If the price goes on to break the first support level at $6.42, it is likely to go to the next support level at $6.25. Assuming the price breaks the second support level, the third support level stands at $6.11.
Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats
Market capitalization of the company is 637.14 million based on 96,682K outstanding shares. Right now, sales total 0 K and income totals -47,910 K. The company made 0 K in profit during its latest quarter, and -11,420 K in sales during its previous quarter.
